Experimental lymphoma drug trial halted early after enrolling 23 patients
NCT ID NCT06088654
First seen Apr 21, 2026 · Last updated May 24, 2026 · Updated 3 times
Summary
This study tested a new drug called IPH6501 in people with a type of blood cancer (non-Hodgkin lymphoma) that had come back or stopped responding to other treatments. The goal was to see if the drug was safe and to find the best dose. The trial was stopped early after enrolling 23 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Austin Health
Heidelberg, Australia
-
Cedars Sinai
Los Angeles, California, 90048, United States
-
Centre Hospitalier Regional Universitaire de Lille
Lille, France
-
Centre Hospitalier Universitaire de Nantes
Nantes, France
-
City of Hope
Duarte, California, 91010, United States
-
Hospices Civils de Lyon
Lyon, 69002, France
-
Hôpital de la Coception
Marseille, 13005, France
-
Icahn School Of Medicine At Mount Sinai
New York, New York, 10029, United States
-
Institute Bergonie
Bordeaux, France
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Monash Health
Clayton, Victoria, 3168, Australia
-
Peninsula Private Hospital
Frankston, Victoria, 3910, Australia
-
Siteman Cancer Center
St Louis, Missouri, 63110, United States
-
Wollongong Private Hospital
Wollongong, New South Wales, 2500, Australia
Conditions
Explore the condition pages connected to this study.